<DOC>
	<DOC>NCT00604383</DOC>
	<brief_summary>This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.</brief_summary>
	<brief_title>Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ruboxistaurin</mesh_term>
	<criteria>Type 1 or Type 2 diabetes mellitus 18 years or older Meet specific requirements for diabetic retinopathy Free of severe or chronically disabling conditions, except diabetes, diabetic retinopathy and diabetic macular edema Hemoglobin A1c (HbA1C) â‰¤13.0% History of panretinal photocoagulation for diabetic retinopathy, conditions that might affect the progression of diabetic retinopathy, or unstable angina Investigators, site personnel directly affiliated with the study and their families Presence of eye disorders that may affect the progression of diabetic retinopathy or cause vision loss Presence of medical disorder, cancer, or elevated laboratory measurements that could represent a safety risk during the study Women who are pregnant, breastfeeding, intend to become pregnant, or who are sexually active without using an acceptable method of birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>